- Camurus’ second CRL for acromegaly drug; Teva details workforce cutsPlus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…Endpoints · 1mo ago↗ source
- STAT+: Novartis doubles down on molecular glue strategySeniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The ReadoutSTAT · 1mo ago↗ source
- Biopharma pay report: Top-paid CSOs, CMOs of 2025Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…Endpoints · 1mo ago